ANALYTICAL METABOLIC INSTRUMENTATION CORE

这一核心是由于我们之前的两个核心，即 细胞生物学和分子生物学核心。后者在过去的几年里有了显著的演变，以应对 我们调查人员不断变化的需求。然而，在2007年1月，杜寿英博士专职从事核心研究 助理离开去继续她的临床培训。这为重新评估如何最好地支持 通过获取中心成员的意见，了解他们目前和未来的需求。至于细胞生物学核心，虽然 其亚细胞器官和设备亚核的仪器基础和服务保持不变 扩大范围，对纯化细胞器和膜制剂的需求大幅下降，原因是 我们调查人员不断变化的需求。这两个发展的结合为我们提供了 有机会审查和重新评估我们的调查人员对所提供资源和服务的需求 通过这两个实体，并将它们重组为本标题下的一个新的、扩大的核心。这个 中心的外部顾问委员会和内部执行委员会向我们提出了我们的需求和 委员会审议了重组的理由，并核准从赠款第3年(即 3/1/07)。因此，核心汇集了已经广泛和迫切需要/使用的仪器基础和 亚细胞-细胞器和设备亚核的分析服务菜单(多检测高效液相色谱) 将以前的分子生物学核心转变为新的和扩展的中央核心(见下文细节)。 此外，对于上述扩大的基础所提供的分析资源和服务，更多的情况-- 通过两个新组建的次级核心增加了抗逆转录病毒药物分析和代谢资源和服务，即：a 基于质谱学的蛋白质组亚核心(蛋白质组亚核)与小分子鉴定/质量 光谱亚核(小分子亚核)。对中央核心和每个核心的详细描述 这两个子核在下面各自的章节中介绍。在此过程中，对南加州大学的支持 遗传医学微阵列设施研究所，是先前分子生物学核心的一个子核心，是 取消，以及与这些服务相关的中心赠款成本。这在一定程度上是因为 减少了对这项服务的兴趣。然而，微阵列服务将在其他情况下保持对 可能需要它们的中心成员。 任命下列教员指导新的核心及其次级核心： 穆拉德·乌克滕斯，博士，中央核心总监(5%努力) 易卜拉欣·赞迪，博士，基于质谱学的蛋白质组亚核心主任(10%努力) 斯坦·路易，制药公司。D.，小分子鉴定/质谱亚核心主任(5%努力) 除了领导中央核心外，Ookhten博士还将与两个次核心协调和密切合作 确保他们的服务符合中心的目标和需求。赞迪博士和 路易将各自指导各自的子核，并将与Ookhten博士就其用途进行沟通 和报道活动。与过去一样，核心董事和次核心董事将被要求报告他们各自的 在执行委员会会议期间的表演。 除了以上几点之外。安德鲁·斯托尔茨博士，前分子生物学核心主任，将继续 免费为中心提供服务，作为调查人员的顾问，他们需要使用一些资源和 以前属于分子生物学核心的仪器。因此，他将协助Ookhten博士进行 最大限度地利用这些资源，以及确定未来必要的设备升级和采购。 中心核心和基于质谱学的蛋白质组亚核心位于Hoffman Medical 研究(HMR)大楼，小分子鉴定/质谱亚核心位于隔壁 在药学院大楼里。

This core resulted from the reorganization and restructuring of two of our previous cores, i.e. the Cell Biology and Molecular Biology Cores. The latter had evolved significantly over the years in response to the shifting needs of our investigators. However, in January 2007, Dr. Shouying Du, the Core's full-time Research Associate left to pursue her clinical training. This provided an opportunity to reassess how to best support the on-going and future needs of the Center members, by obtaining their input. As to the Cell Biology Core, while the instrumentation base and services of its Subcellular-Organelle and Equipment Subcore had kept expanding, the need for purified organelle and membrane preparations had declined substantially, due to shifting needs of our investigators. The combination of these two developments provided us with the opportunity to review and reassess the needs of our investigators for the resources and services offered through these two entities and to restructure them into a new and expanded core under the present title. The Center's external Advisory Board and the internal Executive Committee were presented with our needs and rationale for restructuring and approved the establishment of the present core starting with grant year 3 (i.e. 3/1/07). Thus, the core pooled the already extensive and critically needed/used instrumentation base and the menu of analytical services (multi-detection HPLC) of the Subcellular-Organelle and Equipment Subcore with that of the previous Molecular Biology Core into a new and expanded Central Core (see details below). Furthermore, to the analytical resources and services offered by the expanded base above, additional state-ofthe- art analytical and metabolic resources and services were added through two newly formed subcores, i.e.: a Mass Spectrometry-Based Proteomics Subcore (Proteomic Subcore) and a Small Molecule Identification/Mass Spectrometry Subcore (Small Molecule Subcore). The detailed descriptions of the Central Core and each of the two Subcores are presented in their respective sections below. In the process, support for the USC Institute of Genetic Medicine Microarray Facility, a Subcore of the prior Molecular Biology Core, was eliminated, along with the costs to the Center grant associated with these services. This was done in part due to the reduced interest for this service. However, microarray services will otherwise remain available to the Center Members who may need them. The following faculty were appointed to direct the new core and its subcores: Murad Ookhtens, Ph.D., Central Core Director (5% effort) Ebrahim Zandi, Ph.D., Mass Spectrometry-Based Proteomics Subcore Director (10% effort) Stan Louie, Pharm. D., Small Molecule Identification/Mass Spectrometry Subcore Director (5% effort) Besides directing the Central Core, Dr. Ookhtens will co-ordinate and work closely with the two subcore directors to insure that their services remain responsive to the Center's objectives and needs. Drs. Zandi and Louie will each direct their respective subcores and will communicate with Dr. Ookhtens regarding their usage and reporting activities. As in the past, the core and subcore directors will be required to report their respective performances during the Executive Committee meetings. In addition to the above. Dr. Andrew Stolz, Director of the previous Molecular Biology Core, will continue serving at no cost to the Center, as an advisor to investigators who need the use of some of the resources and instruments that were previously under the Molecular Biology Core. He will thus assist Dr. Ookhtens for the optimum utilization of these, as well as identify essential future equipment upgrades and acquisitions. The Central Core and the Mass Spectrometry-Based Proteomics Subcore are located in the Hoffman Medical Research (HMR) building, with the Small Molecule Identification/Mass Spectrometry Subcore located next door in the School of Pharmacy building.